To evaluate the oncological outcome of histologic variants in bladder cancer patients who underwent radical cystectomy. Materials and Methods: We identified 393 bladder cancer patients who underwent radical cystectomy at single center between January 2007 and August 2014. Patients were divided into 4 groups according to histologic types: pure urothelial cell carcinoma (UC) and squamous, micropapillary, and other variants. Kaplan-Meier analysis was performed to assess recurrence-free (RFS) and overall survivals (OS). The patients were divided into those with pathologic stage and nodal status. Results: Among 393 bladder cancer patients, squamous, micropapillary histologic variants were observed in 38 (9.7%), 26 (6.6%), respectively, whereas 39 had other variant types. Stage T3 cancer occurred in more patients with histologic variant compared with those with pure UC. Pathologic positive nodal status was also frequently found in the histologic variant groups. 
INTRODUCTION
Bladder cancer is the sixth most common cancer in the United States, with more than 430,000 cases diagnosed worldwide. 1 Morbidity and mortality are high, especially in the case of muscle invasion. Multimodal treatment with radical cystectomy and neoadjuvant chemotherapy is preferred. 2 Urothelial cell carcinoma (UC) is the most common pathologic type, accounting for 90% of all bladder cancers. 3 The 2004 World
Health Organization (WHO) classification of UC listed 13 his- Some reports have noted that histologic variants affect oncologic outcome, 6, 7 whereas others have stated that the inclusion of variants in pathological analysis did not impact survival, and discrepancy regarding this still exists to date. [8] [9] [10] Therefore, we aimed to determine the prognostic significance of histologic variants associated with recurrence and progression after radical cystectomy in a single-center cohort of patients with bladder cancer.
MATERIALS AND METHODS

Study Design and Patients
In total, 424 patients underwent radical cystectomy between Recurrence-free survival (RFS) and overall survival (OS) were analyzed according to pathologic T stage using the Kaplan-Meier analysis. The entire cohort was divided into patients with pathologic stage ≤T2 or lower and ≥T3 or higher.
All pathologic reports of radical cystectomy were read by pathologists at our institute. In the surgical characteristics, surgical margins included positive urinary tract resection margins with positive soft tissue margins.
Statistical Analysis
Categorical variables are presented as frequencies and per- The 5-year OS rates were 87.8% and 42.8%, 44.0%, and 51.4%, respectively. The RFS and OS rates for the pure UC group were statistically superior to those of the squamous (p=0.049 and p=0.005, respectively) and other (p=0.005 and p=0.031, respectively) variant groups (Fig. 1A, B) . disease demonstrated no significant difference in RFS and OS rates (Fig. 3) . 
DISCUSSION
We aimed to identify the oncological outcome of UC, including histologic variants, in comparison with pure UC. Almost 25%-30% of patients with UC of the bladder show muscle invasion in the cystectomy specimen, for which radical cystectomy is the standard treatment. 11, 12 Muscle invasive bladder cancer carries a high risk of death because of disease progression, recurrence, and metastasis. 13 Previous studies have reported approximately 10%-40% of bladder cancers show histologic variants on pathology results. 14 Shah et al. 7 reported that among 101 patients, the squamous variant was the most frequent, followed by glandular and micropapillary variants. In patients who underwent radical cystectomy, the squamous variant accounted for approximately 10%-22% of cancers. 6, 10 In our study, the squamous variant also was the most common (9.7%).
The micropapillary variant has been reported in approximately 0.7%-6.0% of cases 15, 16 and occurred in 6.6% of our patients.
Similar to other reports, nested, plasmacytoid differentiation, giant cell, microcystic, lymphoepithelioma-like, lymphoma-like, and plasmacytoid variants were rare in our study.
In several studies, histologic variants were reported to be the contributing factors of poor oncological outcome. One report indicated tumor size and squamous differentiation to be predictors of prognosis and cancer-specific survival. 6 The micropapillary variant has been suggested to be a major factor associated with cancer-related mortality. 10, 16 The plasmacytoid variant also has been reported to be associated with mortality with the micropapillary variant. 10 Also, histologic variants in lymph node positive urothelial bladder cancer have been reported to be a significant factor of worse outcome. 17 In contrast, several studies have indicated that histologic variants were not factors influencing oncological outcome. In a prognostic analysis of squamous and glandular variants, there was no oncologic outcome difference between both variant groups. 18 Indeed, one large study reported that the squamous variant itself did not affect the prognosis. 3 Unlike other reports stating that the micropapillary variant acts as a poor prognostic factor, some studies report no difference compared with pure UC regarding surgical outcome when controlling for pathological factors. 9 Moreover, in a recent study of 303 patients who underwent trimodal bladder-sparing therapy for muscle invasive bladder cancer, histologic variants of UC did not affect oncologic outcome. 8 Our study also concluded that the effect of histologic variant on oncologic outcome in patients who underwent radical cystectomy was not different from that in patients with pure UC. The OS rate of patients with histologic variants in the cohort seemed to be lower than that of patients with pure UC because histologic variants were more commonly of advanced pathologic stage. Each histologic variant group showed no worse outcome than pure UC according to nodal status except for other variants group of nodal negative patients in RFS. In previous study, variant groups were considered to be factors affecting the survival rate on node positive patients. 17 However, we found that there was no significant difference when the histologic variant types were identified in node positive group analysis.
Consequently, there was no significant difference in the survival rate of patients with variants when controlling for pathologic stage and nodal status, also these findings have been supported by several studies. 6, 9, 18 Regarding treatment strategy, Krasnow et al. 8 reported that patients with histologic variants found at TURBT should be advised of the adverse clinical course and cystectomy should be strongly recommended. In this study, we did not investigate the response to chemotherapy, but many studies reported a poor response with neoadjuvant chemotherapy. 19, 20 The amount of his- tologic variants or the mitotic rate has been reported to change significantly after neoadjuvant chemotherapy, and pathologic T stage has been downstaged after neoadjuvant chemotherapy, especially in the case of the squamous variant. The advantage of this study was that we analyzed the recurrence and survival rates according to the pathophysiological characteristics of the histologic variants. According to the stage, histologic variants were identified more often at an advanced stage than pure UC.
The reason for this may be because some variant cells exhibit more rapid growth characteristics or the diagnosis is delayed because of atypical symptoms. 21, 22 In our study BMI was a factor affecting OS (HR, 0.92; 95% CI, 0.87-0.98; p=0.021). One article noted that obesity is associated with an increased risk of bladder cancer. 23, 24 However, there was no report that obesity is related to the survival rate of bladder cancer. The effect of BMI on OS in our study may need to be confirmed in larger cohort studies.
Our study has several limitations. First, we might have an interobserver reliability problem in terms of variant quantity for interpretation of the same specimen during the study period.
Second, survival analysis of pure UC and histologic variants might be affected because of the lack of analysis of the neo- 
CONCLUSIONS
In patients who underwent radical cystectomy, histologic variants were detected more often at a locally advanced stage. The outcome for patients with histologic variants appeared to be worse; however, they were more likely to have advanced clinical and pathological stage disease. So we concluded that though histologic variants have been identified in the radical cystectomy specimen, the treatment for the bladder cancer patients should be performed according to the pathologic stage.
